No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer

CNU IR > Pharmacy and Science > Dept. of Cosmetic Science and institute of cosmetic science > Periodical Articles > Item 310902800/34693

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34693

Title:	No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
Authors:	Kang, Nai-Wen Kuo, Yu-Hsuan Wu, Hung-Chang Ho, Chung-Han Chen, Yi-Chen Yang, Ching-Chieh
Contributors:	Chi Mei Hospital Department of Cosmetic Science, Chia Nan University of Pharmacy & Science Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy & Science Chi Mei Hospital Southern Taiwan University of Science & Technology Department of Pharmacy, Chia Nan University of Pharmacy & Science
Keywords:	concurrent chemoradiotherapy mucoepidermoid carcinoma neck-cancer head radiotherapy management cisplatin outcomes tumors
Date:	2022
Issue Date:	2023-12-11 14:05:28 (UTC+8)
Publisher:	NATURE PORTFOLIO
Abstract:	This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009-2017) with advanced (T3-4 or nodal positivity) major salivary gland cancers, treated post-surgically with adjuvant CRT or RT alone. Overall survival (OS) and disease-specific survival (DSS) evaluated using Kaplan-Meier. Stratified analyses conducted on clinicopathological features. A total of 395 patients were analyzed: 178 (45.1%) received adjuvant CRT; 217 (54.9%) received adjuvant RT alone. Median radiation dose was 66 Gy in 33 fractions. Cisplatin was most common chemotherapy regimen. After a median follow-up of 3.37 years, there was no significant difference in OS or DSS (p=0.1354 and 0.3361, respectively) between groups. Adding chemotherapy to adjuvant RT was not significantly associated with improved OS (adjusted hazard ratio [aHR] 0.94; 95% CI 0.72-1.23) and DSS (aHR 0.96; 95% CI 0.72-1.28). Stratified analysis of clinicopathological features found no significant advantages for improved OS or DSS from adding chemotherapy to adjuvant RT. Thus, in this population database, the use of chemotherapy provided limited survival benefits in advanced major salivary gland cancers after surgical resection.
Relation:	SCIENTIFIC REPORTS, v.12, Article number: 20862
Appears in Collections:	[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles [Dept. of Hospital and Health (including master's program)] Periodical Articles [Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	152	View/Open
s41598-022-25468-9.pdf		1255Kb	Adobe PDF	52	View/Open

Loading...